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Abstract	
Perineural spread (PNS) is a relatively uncommon but important method of metastatic 
spread in cutaneous squamous cell carcinoma (SCC) of the head and neck. PNS is 
defined as cancer spread along a nerve to a site distant from the main tumour bulk and 
should be considered distinct from perineural invasion/ infiltration (PNI), which is the 
microscopic finding of tumour cells infiltrating small nerves within the tumour itself. SCC is 
our second most common malignancy and the head and neck is the most common site to 
be diagnosed with an SCC. The head and neck is an important site for PNS due to the 
high density of both sensory and motor innervation, relatively close proximity to the central 
nervous system once PNS is established and large number of sensitive surrounding 
structures making treatment with surgery and or radiotherapy more challenging. 
Cutaneous SCC of the head and neck with PNS is associated with poorer outcomes in 
terms of local control, regional and distant metastasis and survival when compared to 
lesions without PNS. Little is known about the molecular mechanisms that drive this 
neurotrophic behaviour and much of the work to date has focused on other tumours with a 
predilection for PNS such as pancreatic, prostate and adenoid cystic carcinoma. In our 
own microarray data comparing gene expression from cutaneous SCC with PNS to 
cutaneous SCC with and without PNI the expression of the gene encoding 
transglutaminase 3 (TGM3) was significantly down regulated and the gene encoding lysyl 
oxidase like 2 (LOXL2) was significantly up regulated in tumours with PNS. Human cancer 
cell lines transfected to alter expression of these 2 genes were analysed for neurotrophic 
behaviour using an in vitro mouse dorsal root ganglia (DRG) co-culture assay and a new 
live mouse xenograft model. Results demonstrate the utility of these models as valuable 
tools for studying the mechanisms involved in this complex process and reinforce a 
potential role for LOXL2 and TGM3 in driving PNS in cutaneous SCC. 
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Chapter	1	-	Introduction	
1.1	Non-melanoma	skin	cancer	
Non-melanoma skin cancer (NMSC) which includes basal cell carcinoma (BCC) and 
cutaneous SCC is a major public health concern worldwide but is particularly severe in 
Australia. Australia has the highest incidence of NMSC in the world (1) and NMSC is the 
most commonly diagnosed cancer in Australia with two thirds of Australians diagnosed in 
their lifetime before the age of 70 (2) but the exact incidence and prevalence is difficult to 
define as BCC and SCC diagnoses are not required to be submitted to a central cancer 
register.  
BCC accounts for around two thirds of the NMSC in Australia (1) and while it rarely 
metastasizes to other organs it can be locally invasive and destructive to surrounding 
tissue, cutaneous SCC make up most of the remainder of NMSC diagnoses and is widely 
considered more serious due to its increased potential for invasion and distant metastasis. 
Due to the high incidence of NMSC, it places a large burden on the health system with the 
highest expenditure of any cancer in Australia during 2000-01 at an estimated $264 million 
(2). Over 370,000 Australians are estimated to have been diagnosed and treated for 
NMSC in 2002 (2). In addition to the lack of register data on NMSC, incidence data often 
only records one instance of a particular diagnosis per person per calendar year and 
patients are often treated for multiple NMSCs which underestimates the actual incidence 
of the disease. A study using medicare data of NMSC treatments between 1997 and 2010 
showed that the total number of NMSC treatments in Australia was 412,493 in 1997 and 
increased to 767,347 in 2010, the total medicare benefit expenditure for NMSC treatments 
in 2010 was $93.5 million and the total cost of NMSC including diagnosis, treatment and 
pathology in 2010 was estimated at $511 million and expected to rise to $703 million by 
2015 (3) and this data does not include instances of treatment that occurred in public 
hospitals or cases where treatment was provided without a specimen being submitted for 
histologic examination, potentially further underestimating the true burden of disease. 
NMSC causes significant morbidity and an estimate of this in the form of disability adjusted 
life years (DALY) showed the DALY burden from NMSC was an estimated 4,734 life years 
in 2003, similar to estimates for liver, cervical and uterine cancers (4). While the incidence 
of NMSC has been shown to be increasing, mortality has remained relatively stable. In 
2002 415 Australians died from NMSC and in 2006 this number was 410 (2) illustrating the 
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quality of treatment for NMSC in Australia and the excellent prognosis for small NMSCs 
treated early and adequately.  
The most important risk factor for the development of NMSC is ultraviolet radiation in the 
form of sun exposure, other risk factors include a personal or family history of NMSC or 
melanoma, fair complexion, increased age, male gender, geographic location and 
immunosuppression because of solid organ transplant or other causes. In 2002, a survey 
of NMSC revealed that the incidence increased with age for both BCC and SCC, rates of 
BCC were higher in men than women for age groups older than 55 years and rates of SCC 
were higher in men than women for ages 40 years or over (1). As expected NMSC had a 
predilection for sun exposed areas and the head and neck was the most common site of 
diagnosis for both BCC and SCC, NMSC was more common in people who reported they 
had a skin type that did not tan and in people who lived in a more northerly location in 
Australia (1), all supportive of the role of ultraviolet radiation in skin cancer pathogenesis. 
Medically induced immunosuppression is also a well recognized risk factor for the 
development of NMSC and this is most often seen in solid organ transplant recipients, a 
study of renal transplant patients in Victoria has shown that the risk of NMSC increases 
with the duration of immunosuppression and also that the ratio of SCC:BCC is increased in 
renal transplant recipients (5). This phenomenon has also been demonstrated in patients 
treated with immunosuppresants for auto-immune inflammatory rheumatic diseases as 
patients treated with azathioprine for at least one year have an increased risk of CSCC (6). 
An important prognostic factor in NMSC is the presence of perineural invasion (PNI), 
which occurs in a minority of BCC and SCC and is associated with poorer outcomes. 
1.2	Perineural	spread	(PNS)	
PNS occurs when a tumour gains access to the perineural space of a peripheral nerve and 
spreads along the nerve to a location distal from the primary lesion and is an under 
recognized route of metastatic spread. It often presents months to years after a primary 
skin tumour has been removed. Once a tumour gains access to the perineural space it can 
spread both distally and proximally along the nerve to eventually reach the brainstem, it is 
the experience of this group that spread is contiguous along the nerve although the 
presence of skip lesions is consistently propagated in the literature (7).  
PNS was first reported in the 1800s by a French pathologist who described head and neck 
cancers that grew preferentially along nerves towards the intracranial fossa (8). PNS has 
since been reported in a number of other human cancers such as NMSC, SCC of the head 
and neck and oesophagus, pancreatic carcinoma, prostate carcinoma, adenocarcinoma of 
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the colon and rectum and adenoid cystic carcinoma and is widely recognized as a 
predictor of poor outcome and decreased survival (9). Various definitions and terminology 
used in the literature surrounding PNS have created considerable confusion, the terms 
incidental, microscopic, small nerve, large nerve, named nerve, clinical, perineural 
invasion/ infiltration (PNI) and perineural spread (PNS) have all been used to describe 
different stages of this process.  
In NMSC, PNI is often identified by the pathologist identifying malignant cells within the 
perineural space of a nerve while performing histological examination of the primary 
tumour. This entity is classically termed incidental or microscopic PNI or perineural 
infiltration. On the other hand a patient may present with clinical, neurological signs of 
nerve involvement such as formication (a sensation of ants crawling on the skin), 
paraesthesia, pain or palsy or imaging findings on computed tomography (CT) or magnetic 
resonance imaging (MRI) scans to suggest nerve involvement with tumour. This is termed 
clinical PNI or PNS and tends to behave more aggressively with a generally worse 
prognosis than PNI. Confusion arises with the use of the terms small nerve, large nerve 
and named nerve to describe the size of the nerve involved and define the type of PNS. In 
the literature the term small nerve has been used to define nerves with a diameter of less 
than 0.1mm and large nerve to define nerves with a diameter of greater than 0.1mm, this 
was a response to data showing higher rates of recurrence and metastasis when PNI 
involved nerves >0.1mm (10). Most named nerves have a diameter in the order of 
millimeters in size and it is the opinion of this group that the definition named nerve or 
clinical PNI or PNS is more useful in terms of defining PNS, directing treatment and 
predicting outcome (11). For the duration of this thesis I will use the term PNI to describe 
nerve invasion seen on histology of a primary tumour and PNS to describe the more 
significant situation where a patient has either clinical or radiological findings or both 
consistent with spread along a nerve and away from the original primary.  
It was initially thought that the pathogenesis of PNS involved lymphovascular invasion and 
spread along perineural lymphatic vessels or that it was simply cancer cells gaining access 
to the perineural space by chance and using it as a conduit to spread towards the central 
nervous system (CNS) along the path of least resistance (9). Subsequent studies have 
disputed this showing that there are no lymphatics within the nerve sheath and that a solid 
layer of connective tissue separate the inside of the nerve from the surrounding tumour 
making this anything but a low resistance path for metastasis (9). The pathogenesis 
appears to be more complex and more recent studies have suggested the existence of 
reciprocal signalling interactions between tumour cells and nerves, an in vitro model using 
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mouse DRG and prostate cancer cell lines showed directional neurite outgrowth towards 
cancer cell colonies and retrograde tumour cell migration along neurites towards the 
ganglia of origin (12). This interaction was seen to be further enhanced by the addition of 
supporting stromal cells to the environment (13), further evidence of the complexity of the 
mechanisms involved. The suggestion of reciprocal signalling interactions between tumour 
cells and nerves in the process of PNS led to various studies on the role of neurotrophic 
factors such as nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), glial 
cell line derived neurotrophic factor (GDNF), neurotrophin 3 (NT-3), neutrophin 4/5 (NT-
4/5) and their receptors (9). A study of BDNF in adenoid cystic carcinoma showed that 
BDNF was uniformly expressed in adenoid cystic carcinoma and the authors hypothesized 
that this may be related to the high incidence of PNS in this cancer (14). Miknyoczki found 
that expression of the neurotrophin receptors tropomyosin related kinase A (TrkA), TrkB 
and TrkC was increased in pancreatic ductal adenocarcinoma and that the invasiveness of 
pancreatic cancer cell lines was stimulated in vitro by NT-3 and BDNF (15). All of this data 
suggests that the development of PNS is likely to be multifactorial with complex signalling 
relationships occurring between tumour cells and nerves. 
1.3	Cutaneous	SCC	of	the	head	and	neck	with	PNS	
Cutaneous SCC is the second most commonly diagnosed skin cancer and the head and 
neck is the most common site to be diagnosed with cutaneous SCC. The head and neck is 
also an important anatomical site in terms of PNS due its rich innervation with both 
sensory and motor nerves and close proximity of sensitive surrounding structures that 
make treatment with surgical resection and or radiotherapy more challenging.  
PNS in cutaneous SCC was first described in 1862 when Neumann observed metastatic 
spread along the mental nerve in a patient with a primary lip carcinoma (16). PNS occurs 
in a minority of cases of cutaneous SCC of the head and neck but caries a worse 
prognosis, the incidence varies in the literature due to variation in how diligently tissue 
specimens are examined histologically and the problems with definition outlined earlier. In 
the modern literature Goepfert described a series of 967 head and neck cutaneous SCCs 
in 520 patients treated over a ten year period and noted the incidence of PNS in one or 
more major nerve trunks was 14%, he also noted that the maxillary (V2) and mandibular 
(V3) branches of the trigeminal nerve (CNV) and the facial nerve CNVII) were most often 
involved and that patients with PNS had higher rates of cervical and distant metastases 
particularly intracranial and significantly reduced survival compared to patients without 
PNS (17). The relatively high incidence noted in this report may be due to referral bias as it 
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involves patients referred for specialist treatment in a tertiary centre. Two studies from 
2005 documented an incidence of incidental PNI in cutaneous SCC of 2.6 and 5.95% 
(18,19) and the actual incidence probably lies in this range. It has been shown that nerve 
invasion is more commonly associated with tumours that are recurrent after previous 
treatment, have a location on the mid face, are larger or poorly differentiated (17,19). As 
previously mentioned the nerves most commonly involved in perineural spread of 
cutaneous malignancy are the second (V2) and third (V3) divisions of the trigeminal nerve 
(CNV) and the facial nerve (CNVII) (17,20) but other nerve involvement has also been 
reported such as the great auricular nerve (21). The presence of PNS in cutaneous SCC 
of the head and neck is universally associated with increased rates of local recurrence, 
regional and distant metastasis and decreased survival (7).  
Little is known about the tumour biology that influences neurotrophic behaviour in this 
condition. Previous data has suggested a role for neural cell adhesion molecule (N-CAM) 
in the development of PNS in adenoid cystic carcinoma of the head and neck and mucosal 
squamous cell carcinoma of the head and neck however a study on N-CAM in cutaneous 
SCC of the head and neck showed no expression of N-CAM in specimens with either 
incidental PNI or PNS suggesting no role for N-CAM in PNS in cutaneous SCC of the head 
and neck (22). AlphaB-crystalin, a potential oncogene has also been analysed for a 
potential role in the development of PNS in cutaneous SCC of the head and neck however 
results have shown that its expression is reduced in cutaneous SCC of the head and neck 
with clinical PNI (23). Another group found that FoxP3 expression was increased in 
cutaneous SCC with PNI, FoxP3 stains CD4+ CD25+ regulatory T cells and increased 
staining indicates a higher proportion of these regulatory cells in the tumour infiltrating 
lymphocytes (24).  
In our own microarray data examining gene expression in tissue specimens from patients 
with cutaneous SCC of the head and neck and PNS (unpublished), we found that the 
expression of the gene encoding transglutaminase 3 (TGM3) was significantly reduced 
and expression of the gene encoding lysyl oxidase like 2 (LOXL2) was significantly 
increased in specimens with PNS compared to tumours with and without PNI suggesting a 
potential role for these molecules in the development of PNS with this tumour. 
1.4	Diagnosis	and	staging	
The initial symptoms of PNS can often be subtle and clinicians need to have a high degree 
of suspicion when assessing patients with cutaneous SCC of the head and neck 
particularly when the disease is locally advanced or recurrent in nature. Patients with PNS 
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may present with neurological symptoms like paresthesia or formication (a feeling of ants 
crawling under the skin), pain, numbness or facial weakness depending on which nerve is 
involved and unless these symptoms are specifically sought on history taking they can be 
missed. It is not uncommon for the symptomatology of PNS to be misinterpreted by 
clinicians as trigeminal neuralgia or Bell’s palsy delaying diagnosis and treatment for what 
is actually PNS. A thorough neurological assessment should follow to elucidate signs of 
facial weakness or altered sensation to alert the clinician to the presence of nerve 
involvement.  
Incidental PNI is most commonly diagnosed on routine histology following biopsy or 
excision of a cutaneous lesion. Histologic diagnosis can be problematic and is dependent 
on the number of sections examined, whether any immunohistochemical stains are used 
and the existence of histologic mimics such as peritumoral fibrosis may further confuse the 
pathologist (18). It is generally accepted that detection of malignant cells within any of the 
epineurium, perineurium or endoneurium of the nerve on histology is adequate for a 
diagnosis of PNI, some groups argue that if tumour surrounds greater than 33% of the 
circumference of the nerve that this should also be accepted however not all agree (9). A 
study assessing the efficacy of immunohistochemical stains for s100 and P75NGFR 
compared to hematoxylin and eosin (H&E) stains for the diagnosis of PNI showed that in 
34 cases, PNI was detected in 18% with H&E, 38% with P75NGFR staining and 35% with 
s100 staining (25) showing that the sensitivity can be improved with the addition of 
immunohistochemical stains.  
Imaging studies to both detect the presence and define the extent of PNS have become 
important to assist with planning treatment and predicting outcome. CT and MRI scanning 
are the most commonly used tools for this purpose, imaging findings diagnostic of PNS 
include enlargement or abnormal enhancement of the nerve, obliteration of the normal fat 
plane surrounding the nerve and/or erosion or enlargement of its related bony foramen 
(26). CT will often only detect later signs of PNS such as erosion or enlargement of bony 
foramina whereas MRI is more sensitive and can detect the signs described above plus 
subtle denervation changes in the muscles supplied by involved nerves such as the 
muscles of mastication (trigeminal nerve) or facial expression (facial nerve) (11). Two 
studies looking at imaging findings and outcome found that patients with PNS but no 
findings on imaging performed better in terms of local control and absolute and cause-
specific survival at 5 years compared to patients with imaging positive disease (27,28). 
There is some contention however that these findings may be due to the inclusion of 
patients with paresthesia relating to previous surgery rather than perineural disease being 
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included in the study group (29). It is likely with improvements in magnet strength, MRI 
technology and more focussed imaging that this imaging negative, clinical PNI group will 
reduce in size or even cease to exist. Two studies comparing CT and MRI for the 
diagnosis of PNS in patients with adenoid cystic carcinoma of the head and neck have 
found MRI to be superior (30,31).  
Determining the extent of spread along an involved nerve is crucial in determining whether 
a patient should undergo surgery (including the type of resection), is treated with 
radiotherapy alone or is untreatable. The most commonly used system for describing the 
extent of spread is the zonal classification described by Williams et al (26). Using this 
system PNS is defined as either zone 1- peripheral, zone 2 - central/skull base or zone 3 - 
cisternal depending on the anatomical extent of invasion along the nerve towards the skull 
base. MRI has become the gold standard for the purpose of defining the extent of PNS, a 
study using targeted MRI or MR neurography to compare the extent of disease detected 
radiologically to that present on subsequent histology in 25 patients with clinical PNI 
undergoing surgical resection found that the MRI was 100% sensitive in detecting PNS 
and correctly identified the anatomic spread of disease in 83.3% of cases (32). There was 
one false positive and in 13.3% of cases MRI underestimated the extent of spread 
proximal to the Gasserian ganglion which may have altered management had it been 
detected preoperatively (32).  
The presence of PNI has been recognized as a high-risk feature in non-melanoma skin 
cancer in the most recent and 7th edition of the American Joint Committee on Cancer 
(AJCC) staging manual (33). PNI is now incorporated into the staging system for 
cutaneous SCC and other cutaneous carcinomas as a high-risk feature along with 
anatomical site ear or hair-bearing lip, thickness >2mm, Clark level ≥IV and poorly or 
undifferentiated tumours. The presence of any two or more of these high-risk features 
upstages tumours <2cm in diameter to T2. Cutaneous SCC with spread to the skull base 
via perineural or other route are staged as T4. PNI was added as a staging tool to the 
latest AJCC cancer-staging manual due to emergence of data of its prognostic 
significance. These new guidelines place significant onus on pathologists to report on 
degree of differentiation, tumour thickness, Clark level and the presence of PNI in order to 
accurately stage cutaneous SCC which may prove difficult to implement in clinical practice. 
1.5	Treatment	
It is well accepted that the presence of PNS in cutaneous SCC correlates with aggressive 
behaviour, increased recurrence, metastasis and decreased survival (7). Most agree that 
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surgery with clear margins using either Mohs or the traditional approach is the appropriate 
initial method of treatment for primary NMSC, controversy arises around the role of 
adjuvant radiotherapy.  
A study in 2009 searching the Medline database identified 74 cases with PNI out of 2,449 
with high-risk SCC that were treated with surgery alone or surgery and post-operative 
radiotherapy and found similar outcomes in terms of local recurrence, regional and distant 
metastasis and disease specific death (34), however most patients studied had incidental 
PNI rather than PNS making it difficult to draw any strong conclusions about the role of 
adjuvant radiotherapy in PNS. The other problem with retrospective studies such as this is 
that the patients have not been randomized to the treatment arms and it is likely that 
patients with high-risk features were more likely to receive adjuvant radiotherapy rather 
than surgery as monotherapy. One of the most significant outcome measures in the study 
was the status of the surgical margin as cases with surgical margins reported as clear 
performed better than cases where the status of the margin was not reported (cases with 
margins reported as positive were excluded from the study) (34) further indicating the 
importance of surgery with clear margins for the treatment of cutaneous SCC. This raises 
the question of the appropriate method of surgical treatment, standard surgical resection 
or Mohs micrographic surgery (MMS). A review of studies comparing surgical methods 
revealed that MMS was superior to standard surgery in terms of local control, with rates of 
92-100% and 38-100% respectively (35). A further study by Kropp et al comparing MMS 
plus radiotherapy and non-MMS plus radiotherapy in a group of patients with SCC and 
incidental PNI showed improvements in cause specific survival and local control with MMS 
(36). These differences probably again represent the status of the surgical margin as MMS 
provides a real time assessment of margin during the initial surgical procedure and is thus 
more likely to be a clear resection. It remains unclear in the case of incidental PNI when 
the addition of post-operative radiotherapy is necessary and/or beneficial. Some argue that 
patients with incidental PNI and high-risk features should be considered for adjuvant 
radiotherapy. Such features include recurrent, large or deeply invasive tumours in a mid 
face location with multiple foci of PNI within a single lesion or PNI involving nerves >0.1 
mm or patients that are immunosuppressed, these patients tend to have worse outcomes 
and tend to be offered post-operative radiotherapy.  
The treatment of patients with clinical PNI is less controversial, if disease appears to be 
completely resectable with clear margins then surgical resection with post-operative 
radiotherapy is the treatment of choice. If however on preoperative MRI patients have 
spread to zone 3 as described earlier the chances of gaining clear margins with surgery 
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becomes less likely. In this case pursuing surgery can cause morbidity and spread of the 
disease without significantly improving outcome and these patients are generally offered 
definitive radiotherapy. Some studies have shown comparison data between surgery plus 
radiotherapy versus definitive radiotherapy and have found surgery plus radiotherapy to 
gain superior outcomes, however again these are retrospective data with patients with 
more extensive disease that is less amenable to complete surgical resection more likely to 
be offered definitive radiotherapy (37). When radiotherapy is used in cases of incidental 
PNI with clear surgical margins radiotherapy fields usually encompass the primary site 
plus a surrounding margin of 2-3cm. With clinical PNI or PNS radiotherapy fields are 
extended to involve the course of the involved nerve back to the skull base, which tends to 
cause more treatment related side effects and toxicity. With the recent advances in 
radiotherapy such as intensity modulated radiation therapy (IMRT) it is becoming possible 
to deliver the required dose of radiation in a more targeted fashion avoiding sensitive 
surrounding structures such as the orbit and brain, reducing side effects and toxicity and 
improving outcomes for patients (38).  
Some series have reported an increased rate of metastasis to regional lymph nodes with 
perineural disease and have suggested a role for sentinel lymph node biopsy and/or 
elective radiotherapy to regional lymph nodes (39). Our own data on patients with PNS 
from cutaneous SCC showed the rate of lymph node metastasis to be 6% so we do not 
feel there is a role for elective treatment of the neck in our patient population (40). 
1.6	Prognosis	
Cutaneous SCC with PNI represents a spectrum of disease ranging from small cutaneous 
lesions with a single focus of PNI in a small nerve through to tumours with extensive large 
nerve spread extending to the skull base and prognosis tends to vary accordingly from 
good to poor.  
A report from 2009 of 118 patients with NMSC and incidental or clinical PNI treated with 
either surgery and adjuvant radiotherapy or primary radiotherapy showed significantly 
worse outcomes for the clinical PNI group in terms of local control (90% vs 57%), relapse 
free survival (76% vs 46%), cause specific survival (90% vs 76%) and overall survival 
(69% vs 57%) at 5 years (41). In 2011, a report on 216 patients with skin carcinomas and 
incidental or clinical PNI treated with surgery and post-operative radiotherapy, pre-
operative radiotherapy and surgery or definitive radiotherapy showed significantly reduced 
local control in the clinical PNI group and reduced but not significant differences for overall 
survival, cause-specific survival and local-regional control (42). Panizza et al described 
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their series of 21 patients with cutaneous SCC of the head and neck and clinical PNI 
treated with surgical excision designed to remove the disease en bloc with negative 
margins and post-operative radiotherapy and found that overall survival, disease specific 
survival, recurrence free survival at 5 years were 67.9%, 64.3% and 58.6% respectively 
(43). Recurrence free survival rates for zone 1 disease versus zone 2 disease in this 
series were 80% and 55.1% (43) illustrating the worsening prognosis with progressive 
spread along the nerve to the CNS, patients with zone 3 involvement were deemed 
inoperable and were not included as this was primarily a study on surgical resection. This 
study also showed decreased relapse free survival when the mandibular branch of the 
trigeminal nerve V3 was involved compared to when other nerves were involved although 
this difference did not reach statistical significance (43). A further series of 50 patients with 
PNS from cutaneous SCC of the head and neck treated with surgery and post operative 
radiotherapy showed that recurrence free survival at 5 years was 62% while 5 year 
disease specific survival and overall survival were 75% and 64% respectively (40). 
1.7	Transglutaminase	3	(TGM3)	
TGM3 is an enzyme encoded by the TGM3 gene that is expressed in the suprabasal 
layers of stratified squamous epithelium in the skin and mucosa, it is associated with 
epidermal terminal differentiation by catalyzing the crosslinking of various proteins (44). 
TGM3 has been identified as a potential tumour suppressor gene with studies showing 
that expression is downregulated in a number of cancers including laryngeal carcinoma, 
esophageal SCC, oral and head and neck SCC (44-47) and reduced expression of TGM3 
is associated with poor prognosis in esophageal SCC and head and neck SCC (44,46). It 
has also been reported that there is differential expression of TGM3 in node negative 
compared to node positive oral SCC indicating that loss of TGM3 expression may be 
involved in the development of metastatic potential in oral SCC (48). The level of 
expression of TGM3 has been shown to be associated with the level of differentiation with 
poorly differentiated head and neck SCC expressing lower levels of TGM3 (44).  
Our own data supports a role for TGM3 in the development of PNS in cutaneous SCC of 
the head and neck with previous work demonstrating significantly reduced levels of 
expression in tissue samples of cutaneous SCC of the head and neck with PNS compared 
to tumours with incidental PNI and without PNI (Warren, PhD thesis, in preparation; Boyle 
and Panizza, personal communication). We found that expression of TGM3 was 50 fold 
lower in tumours with PNS compared to SCC without PNI or PNS but expression was 
slightly higher in tumours with PNI compared to tumours without PNI. The expression 
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patterns of TGM3 in cutaneous SCC have not been previously reported and the role of 
TGM3 in the process of PNS is not well understood. An aim of this study is to examine the 
role that TGM3 has in the development of PNS in cutaneous SCC of the head and neck 
and further clarify the mechanism involved. 
1.8	Lysyl	oxidase	like	2	(LOXL2)	
LOXL2 belongs to the Lox family of genes that consists of LOX and LOX-like proteins 1-4. 
It is a copper dependent amine oxidase whose main known function is to promote 
crosslinking of collagen and elastin in the extracellular matrix (ECM).  
LOXL2 has been identified as a potential proto-oncogene with altered expression patterns 
in a number of human cancers, such as breast, colon and head and neck SCC. Perhaps 
the most work has been performed in breast cancer where it has been demonstrated that 
LOXL2 positive tumours are more likely to be estrogen receptor negative or triple negative 
and that LOXL2 expression is a marker of poor prognosis (49). LOXL2 expression is also 
associated with metastasis in basal like breast carcinomas (50). In colon cancer LOXL2 
was found to be highly expressed in cancer-associated fibroblasts and associated with 
poor survival (51). In the head and neck LOXL2 has been identified as a marker of poor 
prognosis in laryngeal SCC (52) and is associated with lymph node metastasis and poor 
outcome in oesophageal SCC (53). The expression of LOXL2 is influenced by hypoxia, an 
important factor in the tumour microenvironment. Studies have demonstrated that LOXL2 
is under the influence of the transcription factor hypoxia inducible factor-1 (HIF-1) (54,55) 
suggesting that upregulation of LOXL2 by cancer cells is part of the adaptive response to 
the hypoxic tumour environment. Epithelial-mesenchymal transition (EMT) is a crucial step 
in tumours gaining metastatic potential where tumour cells reduce cell-cell interaction and 
apical-basal polarity in favour of a more motile and invasive phenotype. LOXL2 has been 
implicated as playing a role in the process of EMT at the molecular level in a number of 
different studies (50,56,57). Targeting LOXL2 has emerged as a potential cancer 
treatment modality with studies showing that an antibody targeting LOXL2 reduced both 
primary and metastatic tumour burden in xenograft mouse models using human breast 
cancer cell lines (58).  
A specific role for LOXL2 in promoting metastasis via the perineural route has not been 
established, our own data comparing gene expression of LOXL2 between tumours with 
PNS to tumours with incidental PNI and without PNI showed significantly increased levels 
of LOXL2 expression in the group with PNS (Warren, PhD thesis, in preparation; Boyle 
and Panizza, personal communication). We found that expression of LOXL2 was 5 fold 
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higher in tumours with PNS compared to tumours without PNI or PNS but expression was 
slightly lower in tumours with PNI compared to tumours without PNI. In this study we 
attempted to address a role for LOXL2 in the development of PNS using an established in 
vitro method and a newly developed in vivo model. 
1.9	Mouse	models	of	PNS	
The desire to better understand the nerve-tumour interaction that drives neurotrophic 
behaviour in vivo has lead to attempts at developing an animal model. A number of 
published models involve placing tumour cells immediately adjacent to nerves or injecting 
directly into the nerve itself, the sciatic nerve of nude mice has commonly been utilised for 
this purpose. This method has been employed for studying adenoid cystic carcinoma with 
the authors placing cells adjacent to the sciatic nerve (59,60) while others have injected 
pancreatic cancer lines directly into the sciatic nerve to establish PNI (61). Some 
investigators have transplanted human nerve tissue subcutaneously into NOD/SCID mice 
and then injected pancreatic cancer cell lines adjacent to the transplanted nerve and 
shown PNI (62). Placing tumour cells in contact with the nerve or injecting into the nerve 
eliminates the process of tumour cells locating and invading the nerve, which are critical 
steps in the establishment of PNI. Groups studying pancreatic cancer have utilised a 
perhaps more physiologic model where pancreatic cancer cell lines were injected into the 
tail of the pancreas of nude mice and were able to demonstrate invasion of retroperitoneal 
nerves by tumour (63). In an in vivo model of head and neck SCC, tumours were 
established on the backs of nude mice and histologic analysis showed PNI of adjacent 
unnamed nerves (64).  
It was felt that none of these existing models adequately mirrored the human condition 
being studied where cutaneous tumours of the head and neck gain access to the cranial 
nerves and spread towards the brainstem. We aimed to develop a new mouse model by 
establishing tumours subcutaneously on the cheek of nude mice, an area richly innervated 
by sensory neurones in the mouse and monitoring for PNS proximally up the V2 nerve, 
which is the most commonly involved nerve in cutaneous SCC of the head and neck with 
PNS. 
1.10	Project	outline	
PNS is an important and under recognised route of metastasis in cutaneous SCC of the 
head and neck and the molecular biology that drives this neurotrophic behaviour is poorly 
understood. Our own data suggest that altered expression of TGM3 and/or LOXL2 may 
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play a role in cancer cells gaining the ability to metastasize via this route. Research in this 
area has been hampered to date by the lack of an adequate animal model of the disease. 
The scope of this thesis is to explore the role of TGM3 and LOXL2 in PNS using an 
established in vitro model and through the development of a novel in vivo model. 
1.11	Hypothesis	
Downregulation of TGM3 and or upregulation of LOXL2 causes cutaneous SCC of the 
head and neck to develop the potential for PNS. 
1.12	Aims	
To produce cutaneous SCC cell lines with reduced expression of TGM3 and 
overexpression of LOXL2 for use in this study. 
To evaluate cell lines with altered expression of TGM3 and LOXL2 for neurotrophic 
behaviour using an established in vitro dorsal root ganglion co-culture model. 
To develop an improved in vivo model to study PNS in cutaneous SCC of the head and 
neck. 
To evaluate cell lines with altered expression of TGM3 and LOXL2 for neurotrophic 
behaviour using this new in vivo model. 
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Chapter	2	-	Materials	and	Methods	
2.1	Cell	culture	
Cell lines were grown and maintained at standard conditions of 5%CO2 at 37°C (Forma 
Scientific water jacketed incubator) in RPMI-1640 (Life Technologies, Scoresby, Victoria) 
containing 10% fetal calf serum (Life Technologies, Scoresby, Victoria), 60 µg/ml penicillin 
(Life Technologies, Scoresby, Victoria) and 100 µg/ml streptomycin (Life Technologies, 
Scoresby, Victoria). Transfected cell lines were maintained with addition of 100 ng/ml 
puromycin (Life Technologies, Scoresby, Victoria) (TGM3 lines) or 100 µg/ml G418 (Life 
Technologies, Scoresby, Victoria) (LOXL2 lines) to the standard culture media described 
above to maintain selection pressure on these transfected lines. Cells were grown in 
NuncTM T75 cell culture treated flasks (ThermoFisher Scientific, Waltham, MA) until 90% 
confluent and detached using a solution containing 0.25% trypsin (Life Technologies, 
Scoresby, Victoria), 3.8% versene in Dulbecco’s salt solution (QIMR media facility). 
2.2	Cell	lines	
A431 is a human cell line developed from an epidermoid carcinoma of an 85 year old 
female patient and was developed by Giard et al (65), Colo16 is a human squamous cell 
carcinoma cell line developed from a 59 year old female with metastatic SCC from a 
cutaneous primary and was first described in 1975 (66). These cell lines have been widely 
used for studying cutaneous squamous cell carcinoma and are also known to form 
tumours when injected into immunosuppressed nude mice making them suitable for use in 
this work. Cells tested negative for mycoplasma contamination and cell line identity was 
confirmed using STR profiling. 
LOXL2 and TGM3 were selected for this study based on microarray data from this 
laboratory demonstrating altered expression patterns in cutaneous SCC with PNS 
(Warren, PhD thesis, in preparation; Boyle and Panizza, personal communication). Genes 
that were differentially expressed greater than a 5-fold level between cutaneous SCC with 
or without PNS were identified using statistical analysis with multiple testing correction. 
LOXL2 was found to be highly expressed in cutaneous SCC with PNS, while TGM3 was 
significantly reduced in cutaneous SCC with PNS. Importantly, these findings were 
replicated in an additional set of tumours (validation set; 27 cutaneous SCC without neural 
invasion, 27 cutaneous SCC with small nerve invasion and 31 cutaneous SCC with PNS), 
using an alternative method of detection (immunohistochemistry). Literature searches 
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were conducted using the terms LOXL2, TGM3, cancer, metastasis and perineural 
revealing published data implicating TGM3 as a tumour suppressor gene, LOXL2 as a 
proto-oncogene and a potential role for both genes in metastasis of other human cancers. 
These two genes had not been assessed previously for a role in PNS and have functions 
in differentiation and epithelial to mesenchymal transition suggesting a possible function in 
tumour progression and metastasis. Based on this, these genes were selected for ongoing 
experiments. 
Cells overexpressing LOXL2 had been created previously using A431 and Colo16 cell 
lines and were available for use in the laboratory (Dr Glen Boyle, Level 8, CBCRC, QIMR 
Berghofer Medical Research Institute, Herston, Qld). These lines along with matched 
empty vector controls were resuscitated from liquid nitrogen and expanded under cell 
culture conditions listed above in standard media with the addition of 100 µg/ml G418 to 
maintain selection pressure, once 90% confluent cells were scraped, washed with cold 
phosphate buffered saline (PBS), pelleted and stored at -20°C for western blot analysis. 
To develop TGM3 knockdown cell lines, A431 and Colo16 cells were plated into NuncTM 6 
well plates (ThermoFisher Scientific, Waltham, MA) at a density that allowed cells to be 
90% confluent after a 24 hour incubation. After 24 hours, media was replaced with Opti-
MEM media (ThermoFisher Scientific, Waltham, MA) containing 10 µl of lipofectamineTM 
2000 (ThermoFisher Scientific, Waltham, MA) and 4 µg of a short hairpin RNA construct 
targeting TGM3 expression and incubated overnight. The following day cells were 
trypsinised and transferred to NuncTM T25 cell culture treated flasks (ThermoFisher 
Scientific, Waltham, MA) with standard cell culture media containing 500 ng/ml puromycin 
for selection of transfected cells. 4 different shRNA constructs (846A, 846B, 846C and 
846D), a scrambled shRNA control construct (0313) and a lipofectamine only control were 
created for both cell lines, shRNA constructs had been created previously and were 
available for use in the laboratory (Dr Glen Boyle, Level 8, CBCRC, QIMR Berghofer 
Medical Research Institute, Herston, Qld) sequences are shown Figure 1. Once 
lipofectamine only control cells were all dead the concentration of puromycin was reduced 
to 100 ng/ml and cells were expanded, stored at -20°C for western blot analysis and at -
80°C for use in ongoing experiments. 
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Figure 1 - shRNA sequences used for knockdown of TGM3 
0313 = scrambled control, 846A-846D = knockdown sequences targeting TGM3 expression 
 
2.3	Western	blot	analysis	
Cells were lysed in 150 µl of cell lysis buffer (20% glycerol, 1% SDS, 10 mM Tris pH 7.4, 2 
mM phenylmethylsulfonyl fluoride (PMSF), 1 × Protease Inhibitor Cocktail (Roche)) and 
were sonicated (Branson Sonifier 250); for 45 s at 4°C, with a duty cycle of 30% and 
output control of 3. Cell lysates were then centrifuged (13200 rpm for 15 min at 4°C) to 
isolate a soluble fraction, which was transferred to a fresh microfuge tube for protein 
quantitation. 
Bovine Serum Albumin (BSA) protein standards (Pierce Chemical Corporation; Rockford, 
IL) were used to quantify the amount of protein in each sample. BSA working reagent (100 
µl of 50 parts reagent A: 1 part reagent B) from the BSA protein assay kit (Pierce Chemical 
Corporation, Rockford, IL) was added to duplicates of samples and standards into a 96 
well plate. The plate was then incubated at 37°C for 30 min and read at 654 nm with the 
ELISA plate reader (Molecular Devices Versamax tunable microplate reader). The 
concentration of protein in the samples was determined by interpolations on the standard 
curve.  
From results of the standard curve, twenty micrograms of protein was applied to a 5-10% 
SDS- PAGE minigel system, alongside 10 µl of BenchMarkTM Prestained Protein Ladder 
(Gibco; Carslbad, CA), and electrophoresed at 200 V for 45min at RT. A 5% stacking gel 
and a 10% resolving gel was prepared and samples were loaded in SDS loading buffer 
(100 mM Tris-HCl pH 6.8, 4% w/v SDS, 0.2% w/v Bromophenol Blue, 20% v/v glycerol, 
100 mM DTT (ICN), 10% PMSF (Sigma)) and made up to a final concentration of 2 µg/µl 
using cell lysis buffer. Samples were then denatured at 95°C for 5 min in a heating block 
(Ratek Instruments Single Dry Block Heater) prior to loading. Electrophoresis was 
performed in a Bio-Rad tank in 1 × Running Buffer (25 mM Tris unbuffered, 250 mM 
glycine, 0.1% SDS). 
CCTGGACCATCATCTACAACGGCACGCTT846D
AGAAGGCTCTGACCAGGAAAGACAAGTGT846C
TGGCTGGAACTTTGGACAGTTTGAAGAAG846B
CGCATCACACAGACAAGTTCTCCAGCCAG846A
GCACTACCAGAGCTAACTCAGATAGTACT0313
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Proteins were transferred by electrophoresis from the polyacrylamide gel to Hybond-C 
nitrocellulose membrane (Amersham Pharmacia) in electroblot buffer (200 mM Glycine, 
250 mM Tris, 20% v/v methanol (Fronine Pty Ltd; Riverstone, New South Wales)) on a 
transblot apparatus (BioRad Laboratories; Hercules, CA) at 150 mA for 3 hr at 4°C. 
Nitrocellulose blots were blocked with Blotto, (5% w/v non-fat dry milk (Diploma, 
Melbourne, Australia) 0.5% Tween 20 in PBS), for 90 min at RT. Blots were then 
incubated with the primary antibody in 2 ml of Blotto overnight at 4°C on a rotator. Blots 
were washed with 0.5% v/v Tween 20 in PBS (2 × 2 min; 3 × 5 min) on an orbital shaker 
(Bioline) and incubated with the appropriate secondary antibody made up in 2 ml Blotto, 
for 90 min at RT on the rotator. Blots were then washed as previously with 0.5% Tween 20 
in PBS and antibody detection is performed using the enhanced chemiluminescence 
(ECL) detection method (NEN). Following a 1 minute incubation in 750 µl Enhanced 
Luminol Reagent and 750 µl Oxidising Reagent, blots were imaged using X- OMAT 
autoradiography film (Kodak; Rochester, NY). 
2.4	Cellular	proliferation	assays	
A431 cell lines transfected to down regulate expression of TGM3 were assessed for 
proliferation ability in vitro. The parental A431 cell line, the scrambled shRNA control line 
0313 and the TGM3 knockdown cell lines 846B and 846D were counted using a 
haemocytometer (Fuchs Rosenthal Dark Lines) and seeded at 2 × 103 cells/well (5 × 103 
cells/well for initial experiment) into 8 × NuncTM 96 well flat bottom plates (ThermoFisher 
Scientific, Waltham, MA), all plates were incubated at 37°C. Plates were fixed at 24 h 
intervals by discarding media, rinsing once with PBS and fixing with methylated spirits 
before storing at 4°C prior to analysis using a Sulforhodamine B (SRB) assay. For the SRB 
assay plates were washed with tap water and stained with 50 µl/well of 0.4% SRB (Sigma) 
in 1% Acetic acid. After 15 minutes the SRB was discarded and the plates were washed 
with 1% acetic acid three times. 100 µl of 10 mM Tris base (unbuffered, pH 9) was added 
to each well before reading at 564 nm on an ELISA reader (VERSA max tunable micoplate 
reader – Molecular Devices). An average blank absorbance of 0.04 was subtracted from 
all experimental data and the student’s t-test was used to analyse data for statistical 
significance. 
2.5	Clonogenicity	assays	
Newly transfected A431 cell lines were assessed for colony forming ability in vitro, cultured 
cells were counted with a haemocytometer (Fuchs Rosenthal Dark Lines) and plated in 
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duplicate into NuncTM 6 well plates (ThermoFisher Scientific, Waltham, MA) at a density of 
2.5 × 103/well and 10 × 103/well and allowed to grow in standard media for 21 days. Media 
was changed as necessary during the 3 week period based on media colour change and 
was changed on all plates simultaneously if required. After 21 days, media was removed, 
plates washed with PBS and cells were fixed with methylated spirits. After fixation, 
methylated spirits was removed, plates washed in tap water and stained with 0.5% w/v 
crystal violet (Sigma-Aldrich, Castle Hill, NSW) for 10 min. Following staining, excess 
crystal violet was removed by washing with tap water and plates were allowed to air dry 
prior to scanning on a standard A4 flat bed scanner for image analysis. An independent 
observer who was blinded to the experimental condition counted colonies manually. 
Plating efficiency was calculated by expressing the number of colonies formed as a 
percentage of the number of cells plated and statistical analysis was performed using the 
student’s t-test. 
2.6	Dorsal	root	ganglia	co-culture	assay	
2.6.1	Optimisation	
In vitro experiments were based on a previously published model of PNI using mouse 
DRG and prostate cancer cell lines (12). Briefly, DRG were dissected from a recently 
euthanized mouse and imbedded in Matrigel matrix (Corning, Corning, NY) adjacent to 
cancer cell lines and observed over time in culture for PNI microscopically. In initial 
experiments using this model it proved difficult to accurately control the position of the 
cancer cell lines relative to the mouse DRG making results difficult to interpret. In an 
attempt to improve the model the Ibidi tissue culture insert (Ibidi, Germany) was used to 
allow for accurate placement of cell lines on the tissue culture vessel. Cell lines were 
grown to 90% confluence and seeded in fresh standard culture media plus 100 ng/ml 
puromycin or 100 µg/ml G418 to maintain selection pressure into Ibidi tissue culture inserts 
as per manufacturer directions that had been attached to NuncTM 6 well plates 
(ThermoFisher scientific, Waltham, MA) and incubated overnight to allow cells to attach. 
The following day a 4-7 week old C57Bl/6 mouse was euthanized using CO2 and cervical 
dislocation, DRG from cervical, thoracic and lumbar levels were dissected using a 
dissecting microscope using aseptic conditions and transferred to a NuncTM 24 well plate 
(ThermoFisher scientific, Waltham, MA) containing fresh tissue culture media. Media was 
then suctioned from adherent tumour cell lines and the tissue culture inserts removed with 
sterile forceps leaving adherent cells behind. A DRG was then placed adjacent to each 
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area of adherent cells under aseptic conditions and the DRG and cells covered with 20 µl 
of Matrigel matrix (Corning, Corning, NY), after setting the Matrigel by placing at 37°C for 
30 min, 5 ml of fresh culture media was added to each well without the addition of 
puromycin or G418 as these affected the growth of the DRG. Co-cultures were then 
placed in a humidified incubator at 37°C plus 5% CO2 and were imaged regularly to 
document the interaction and presence of PNI using an EVOS FL cell imaging system 
(ThermoFisher Scientific, Waltham, MA). As this model did not allow for cell migration 
attempts to improve the published method were abandoned and subsequent experiments 
were performed as in (12). 
2.6.2	Experimental	model	used	
Tumour cell lines and mouse DRG were prepared as described above, a single DRG was 
placed in the centre of a NuncTM 6 well plate (ThermoFisher scientific, Waltham, MA) and 
covered with 20 µl of Matrigel matrix (Corning, Corning, NY), 2.0 × 104 of the tumour cell 
lines were then placed in an adjacent and contiguous drop of Matrigel while keeping the 
culture vessel at 4°C to maintain the fluidity of the Matrigel. The culture vessel was placed 
at 37°C for 30 min to set the Matrigel followed by the addition of 5 ml of fresh culture 
media without puromycin or G418. Co-cultures were then placed in a humidified incubator 
at 37°C plus 5% CO2 and were imaged regularly to document the interaction and presence 
of PNI and PNS using an EVOS FL cell imaging system (ThermoFisher Scientific, 
Waltham, MA). The interaction was graded from nil to spread depending on the degree of 
PNS that had occurred. Scores of nil were given when there was no contact between the 
DRG neurites and tumour cells (or if the DRG had failed to survive in culture), contact was 
when neurites and cells made contact but no migration of cells towards the DRG of origin 
had occurred, invasion was contact plus migration towards but not reaching the DRG and 
spread was when tumour cells had migrated retrograde along the neurites to reach the 
DRG itself, Table 1. 
 
Table 1 - Grading system used for DRG co-culture assay 
Nil	 No	contact	between	tumour	cells	and	neurites	(or	DRG	dead)	
Contact	 Contact	between	tumour	cells	and	neurites	but	no	migration	
Invasion	 Contact	plus	migration	towards	but	not	reaching	DRG	
Spread	 Migration	of	tumour	cells	along	neurites	to	reach	DRG	
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2.7	In	vivo	mouse	model	
All animal work was performed in accordance with NHMRC Animal Welfare Guidelines in a 
pathogen-free animal facility at the QIMR Berghofer Medical Research Institute Animal 
House and all experimentation was approved by QIMR- Animal Ethics Committee. Mice 
were kept in cages equipped with air filters, sterile feed and water and were regularly 
maintained by Animal House Facility staff members. All mice were handled in aseptic 
conditions in accordance with animal welfare and ethical guidelines. 
2.7.1	Optimisation	of	mouse	model	
Previous work in the Parsons lab using tumour cell lines in xenograft models had shown 
that injection of 2.0 × 106 cells/site on the back of nude mice resulted in reliable tumour 
formation. As PNS was likely to be a slow process even in an immunosuppressed mouse 
model we wanted to inject the smallest number of cells possible that would result in tumour 
formation to allow for slow tumour growth and time for PNS to occur. The head and neck 
has a rich blood supply and it is likely that due to this fewer cells per injection would be 
required for tumour establishment to occur. In an initial experiment using an A431 cell line 
7.0 × 105 cells/site was injected into ten 6 week old Balb/c nude mice (Animal Resources 
Centre, Canning Vale, WA). Animals were anaesthetized by placing in an induction 
chamber containing Isoflurane, once anaesthetized 20 µl of the cell suspension was 
injected subcutaneously into the snout of the mouse in the region of the whiskers as this 
site is richly innervated by sensory nerve endings of the maxillary division of the trigeminal 
nerve. Injections were performed with the needle pointing towards the snout, the bevel 
facing up and the needle at an angle less than 30° to avoid injecting the tumour cells 
directly into the V2 nerve, infraorbital foramen or through into the nasal cavity. Inoculation 
was considered successful when a subcutaneous swelling was visible in the cheek region, 
deep to the whiskers of the animal post injection. In this initial experiment all mice grew 
tumours rapidly and were sacrificed at day 20. Subsequently a range of cell numbers was 
injected from 1.0 × 105 - 5.0 × 105 for both the Colo16 and A431 cell lines. Five 6 week old 
Balb/c nude mice (Animal Resources Centre, Canning Vale, WA) were used for each cell 
line and each mouse was injected with 1.0 × 105, 2.0 × 105, 3.0 × 105, 4.0 × 105 or 5.0 × 
105 cells/injection into the V2 region bilaterally using the technique outlined above. Once 
inoculated, animals were monitored every 48 hours for tumour growth and once visible, 
tumour measurements were taken using digital callipers twice weekly and statistical 
analysis of tumour volume was performed using the student’s t-test. Tumours were 
allowed to grow for 90 days but animals were sacrificed earlier if tumour size reached 500 
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mm3, skin overlying tumours became ulcerated or if animals were losing weight, showing 
evidence of malocclusion, appearing distressed or unwell. At the experimental end point 
tissue was harvested for histology and examined for the presence of PNS as described 
below. 
2.7.2	Mouse	model	
For definitive in vivo experiments 6 cell lines were used; the parental A431 cell line, a 
scrambled shRNA control A431-0313 and two TGM3 knockdown lines A431-846B and 
A431-846D as well as the LOXL2 overexpression cell line A431-LOXL2 and a matched 
control A431-EV control, Table 2. Cell lines were expanded and harvested as previously 
described, resuspended at 1.0 × 106/ml in standard media, placed on ice and transferred 
to the animal facility for injection. 4 week old Balb/c nude mice (Animal Resources Centre, 
Canning Vale, WA) were anaesthetized by placing in an induction chamber containing 
Isoflurane, once anaesthetized 20 µl of the cell suspension (i.e. 2.0 × 104 cells/site) was 
injected subcutaneously into the V2 region using the technique described above. Animals 
were placed in cage labelled with the experimental treatment they had received and as an 
added safety measure control cell lines were always injected on the left side of the head 
and genetically modified cell lines on the right. Five animals were used for each 
experimental group. Once inoculated, animals were monitored as described above and at 
the experimental end point tissue was harvested for histology and examined for the 
presence of PNS as described below. 
 
Table 2 - Cell lines used for definitive in vivo experiments 
 
 
2.8	Histopathology	
Once the experimental end point was reached animals were euthanized using CO2 and 
cervical dislocation, the neck was transected at the level of the skull base and the foramen 
magnum opened to allow formalin to penetrate the CNS. The whole mouse head was then 
placed in formalin and transferred to the histology department at QIMR for processing, if 
there was going to be any delay in processing, tissues were transferred to 70% ethanol 
after 24 hours in formalin prior to delivery to the histology department. Following fixation, 
tissues were mounted in blocks and transverse sections were taken through the mouse 
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head at 90 degrees to the plane of the maxillary division of the trigeminal nerve at various 
levels between the snout and the skull base to allow for determination of the extent of any 
large nerve PNS along this nerve, as well as sections through the tumour to assess for the 
presence of incidental or microscopic PNI. As it has been shown that the use of 
immunohistochemical stains can increase the sensitivity of detection of PNS over H&E 
stains alone, sections were stained with H&E along with immunohistochemistry stains for 
s100 and cytokeratin AE1/AE3. S100 was used to stain nerves in the sections and 
cytokeratin AE1/AE3 to stain tumour cells and sections were assessed for co-localisation 
of these two markers as an indicator of PNS. Sections were analysed by a human 
histopathologist for the presence of PNS, which was graded according to the presence of 
PNS or incidental PNI and the distance of any large nerve spread along V2 towards the 
skull base. 
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Chapter	3	-	Results	
3.1	Transfection	of	cell	lines	
Tumour cell lines with reduced expression of TGM3 were created in A431 and Colo16 cell 
lines by transfecting with shRNA targeting TGM3 expression. Four different shRNA 
constructs (846A, 846B, 846C and 846D) and a scrambled shRNA control construct 
(0313) were used and transfected cells were selected using antibiotic resistance to 
puromycin. Western blot analysis demonstrated stable knockdown of TGM3 with two of the 
shRNA constructs (846B and 846D) in the A431 cell line (Figure 2). Transfections were 
successful in the Colo16 cell line as evidenced by the presence of antibiotic resistance and 
expression of GFP but stable knockdown of TGM3 did not occur for any of the four shRNA 
constructs in the Colo16 line. Actin was used as a protein loading control and GFP to 
confirm presence of the vector (Figure 2). 
 
Figure 2 - Western blot analysis of TGM3 expression in transfected A431 and Colo16 cell lines 
Reduced expression of TGM3 in A431 cell lines transfected with 846B (A431-846B) and 846D (A431-846D) 
shRNA, no change in expression in Colo16 cell lines. 0313 = scrambled control. Actin was used as a protein 
loading control and GFP to confirm presence of the vector. 
 
A431 and Colo16 cells lines transfected to overexpress LOXL2 were already available in 
laboratory (Dr Glen Boyle, Level 8 CBCRC, QIMR, Herston, Qld). These cell lines were 
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resuscitated from liquid nitrogen, expanded while maintaining selection pressure with 
G418 and prepared for western blot analysis. Western blot analysis of these cell lines 
revealed increased expression of LOXL2 in the A431 but not the Colo16 cell line. Actin 
was used as a protein loading control (Figure 3). 
 
Figure 3 - Western blot analysis of LOXL2 expression in A431 and Colo16 cell lines 
Increased expression of LOXL2 in transfected A431 cell line (A431-LOXL2) but not Colo16 cell line. EV 
control = empty vector control. Actin was used as a protein loading control. 
 
Cell lines were selected for ongoing experiments based on these results. For TGM3 
experiments 4 cell lines were used, the parental A431 cell line, the scrambled shRNA 
control A431 cell line (A431-0313) and the 2 TGM3 knockdown A431 cell lines (A431-
846B and A431-846D). For LOXL2 experiments 2 cell lines were used, the empty vector 
control A431 cell line (A431-EV Control) and the LOXL2 over expression A431 cell line 
(A431-LOXL2). As none of the transfections in the Colo16 cell lines were effective in 
altering the expression of TGM3 or LOXL2 these cell lines were not used in any further 
experiments. 
3.2	Proliferation	assays	
The cell lines from above were examined for proliferation ability in vitro using a standard 
SRB proliferation assay. The parental A431 cell line, the scrambled shRNA control line 
(A431-0313) and the two TGM3 knockdown lines (A431-846B and A431-846D) were 
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plated at a concentration of 5000 cells/well into 96 well plates and cultured under standard 
conditions. Plates were fixed at 24-hour intervals for 1 week and cell density measured 
using a SRB assay. At 5000/well, there appeared to be reduced proliferation ability in the 
A431-846B TGM3 knockdown line but all cell lines became confluent around day 4 and 
then became non-viable making it difficult to monitor trends in cell growth over the whole 
week (Figure 4). 
 
 
Figure 4 - Proliferation assay of transfected A431 cell lines (5000 cells/well) 
Cells were plated at 5000 cells/well in 96 well plates and absorbance was measured daily for 7 days for each 
of the 4 cell lines. Parental = parental A431 cell line, control = 0313 scrambled control, TGM3B = 846B 
knockdown, TGM3D = 846D knockdown. Data shown is mean +/- standard deviation of 24 wells. Cell lines 
became confluent at day 4. 
 
In subsequent assays 2000 cells/well were seeded for each cell type, in the first trial both 
TGM3 downregulated cell lines showed reduced proliferation compared to the parental 
and control cell lines with a statistically significant difference evident on day 4 and day 5 
(p<0.05) (Figure 5 left panel). In the second trial, the A431-846B TGM3 knockdown line 
again showed reduced proliferation compared to other cell lines with the difference 
significant on day 4 and day 5 (p<0.05) (Figure 5 right panel). 
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Figure 5 - Proliferation assay of transfected A431 cell lines (2000 cells/well) 
Cells were plated at 2000 cells/well in 96 well plates and absorbance was measured daily for 7 days for each 
of the 4 cell lines. Parental = parental A431 cell line, control = 0313 scrambled control, TGM3B = 846B 
knockdown, TGM3D = 846D knockdown. Data shown is mean +/- standard deviation of 24 wells and 
demonstrates significantly reduced proliferation ability in the TGM3 knockdown cell lines TGM3B and 
TGM3D on one trial (left panel) and TGM3B in another (right panel) at day 4 and day 5. 
 
These results suggest reduced proliferation ability in the A431-846B cell line transfected to 
downregulate the expression of TGM3. 
3.3	Colony	forming	assays	
The A431 cell lines with constitutive TGM3 knockdown were assessed for signs of tumour 
cell aggression using a colony forming assay in vitro post transfection. The two knockdown 
lines A431-846B and A431-846D were run in this assay alongside the parental A431 line 
and the scrambled shRNA control line A431-0313. Cells were plated into 6 well plates at a 
concentration of 2500 cells/well and 10000 cells/well and cultured under standard 
conditions, before being fixed, stained with crystal violet and imaged for analysis (Figure 6 
& Figure 7). 
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Figure 6 - Colony forming assay of transfected A431 cell lines (2500 cells/well) 
Cells were plated at 2500 cells/well in 6 well plates and cultured for 21 days before fixation and staining with 
crystal violet. A431 - Parental = parental A431 cell line, A431 - 0313 = 0313 scrambled control, A431 – 846B 
= 846B knockdown, A431 - 846D = 846D knockdown. 
 
 
Figure 7 - Colony forming assay of transfected cell lines (10000 cells/well) 
Cells were plated at 10000 cells/well in 6 well plates and cultured for 21 days before fixation and staining 
with crystal violet. A431 - Parental = parental A431 cell line, A431 - 0313 = 0313 scrambled control, A431 – 
846B = 846B knockdown, A431 - 846D = 846D knockdown. 
 
Plates that were seeded at 10000 cells/well resulted in a colony density that was too high 
to count accurately, as did the parental A431 cell line when seeded at 2500 cells/well. 
Transfected cell lines clearly showed a reduced colony forming ability compared to the 
parental cell line (Figure 6), although this could not be quantified due to the high colony 
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density for the parental cell line. Colonies were counted for the A431 scrambled shRNA 
control cell line (A431-0313) and the two TGM3 knockdown lines (A431-846B and A431-
846D) and expressed as a percentage of the plated cell number to obtain the plating 
efficiency. The two TGM3 knockdown cell lines had a plating efficiency that was 
significantly lower (2.52% and 2.3%) than the scrambled shRNA control line (4.92%), 
(Figure 8) (n=2). 
 
 
Figure 8 - Colony forming ability of transfected A431 cell lines 
Cells were plated at 2500 cells/well in 6 well plates and cultured for 21 days before fixation, staining with 
crystal violet and counting of colonies. 0313 = scrambled control, TGM3B = 846B knockdown, TGM3D = 
846D knockdown. Plating efficiency was calculated by expressing the number of colonies counted as a 
percentage of the cell number plated. Data shown is mean +/- standard deviation of 4 wells (duplicates from 
2 separate experiments) and demonstrates significantly reduced colony forming ability of both TGM3 
knockdown cell lines. 
 
3.4	Optimisation	of	in	vitro	co-culture	assay	
Cell lines were assessed for their capacity for PNS in vitro using a mouse dorsal root 
ganglia co-culture model published previously (12). In initial experiments using the 
published methodology it proved difficult to control the position of the cell lines relative to 
the position of the DRG causing results to be inconsistent (not shown). In an attempt to 
resolve these inconsistencies cell lines were seeded into Ibidi tissue culture inserts (Ibidi, 
Germany) and allowed to become adherent to the tissue culture vessel before placing the 
DRG adjacent to the adherent cells and securing in place with Matrigel matrix (Corning, 
Corning, NY). Using this modification to the model there was greater consistency in the 
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placement of cells relative to the DRG in the culture vessel allowing for greater control 
across experimental groups. This method was tested using the parental Colo16 cell line 
(n=6) and results are demonstrated in Figure 9. DRG neurite outgrowth was first observed 
on day 2-3 and was extensive by day 7, directional outgrowth of neurites towards the cell 
line was not observed and rather seemed to occur in a random pattern in all directions. 
There appeared to be no change in neurite outgrowth in the presence of the tumour cell 
line with neurite area being equal between the DRG cultured with cell lines and those 
cultured alone (not shown). Importantly PNS was not observed in any of the 6 replicates of 
this experiment, no cell migration from the original position was observed over the 7 days 
(Figure 9). 
 
 
Figure 9 – Mouse DRG co-culture assay with parental Colo16 cell line 
Parental Colo16 cell line cultured adherent to culture vessel prior to placing mouse DRG and securing with 
Matrigel. Each column represents a single co-culture imaged over 7 days demonstrating neurite outgrowth 
from the DRG but no cell migration or PNS. 
 
Newly created A431 cell lines transfected to down-regulate expression of TGM3 were also 
tested using this assay. The two TGM3 knockdown lines A431-846B and A431-846D 
along with the scrambled shRNA control line A431-0313 and the parental A431 cell line 
were cultured with mouse DRG for 2 weeks. Again neurite outgrowth occurred early and in 
a random fashion and there was no difference in neurite area between co-cultures and 
DRG cultured alone (Figure 10). Contact between neurites and tumour cells was evident 
between day 7 and day 11 for all groups but no cell migration or PNI appeared in any 
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group and tumour cells began to appear non-viable in the second week. Co-cultures were 
performed in duplicate in 2 separate experiments (n=4) and results were consistent across 
all experiments. A representative example from each group is displayed (Figure 10). 
 
 
Figure 10 – Mouse DRG co-culture assay with transfected A431 cell lines 
Transfected A431 cell lines cultured adherent to culture vessel prior to placing mouse DRG and securing 
with Matrigel. DRG alone = DRG cultured alone, parental = parental A431 cell line, control = 0313 scrambled 
control, TGM3B = 846B knockdown, TGM3D = 846D knockdown. Each column represents a single co-
culture imaged over 7 days demonstrating neurite outgrowth from the DRG but no cell migration or PNS. 
 
Using this method with cells adherent to the culture vessel and covered with Matrigel it 
appeared that tumour cells were unable to migrate or even proliferate and survive and this 
modification to the method was abandoned in favour of the published version for future 
experiments. 
3.5	DRG	co-culture	assay	
3.5.1	TGM3	
A431 cell lines transfected to alter their expression of TGM3 were assessed for 
neurotrophic behaviour in vitro using a mouse DRG and tumour cell co-culture model as 
published previously (12). Cell lines were cultured with mouse DRG for 2 weeks after 
being placed together in an adjacent and contiguous drop of Matrigel matrix as per the 
published method. Four cell lines were run in this assay, the parental A431 cell line, the 
scrambled shRNA control cell line A431-0313 and the two TGM3 knockdown cell lines 
 31 
A431-846B and A431-846D. Cultures were assessed regularly for the presence of PNS 
which was graded from nil to spread depending on the degree of PNS that had occurred. 
Scores of nil were given when there was no contact between the DRG neurites and 
tumour cells (or if the DRG had failed to survive in culture), contact was when neurites and 
cells made contact but no migration of cells towards the DRG of origin had occurred, 
invasion was contact plus migration towards but not reaching the DRG and spread was 
when tumour cells had migrated retrograde along the neurites to reach the DRG itself. 
Results are shown in Table 3, in some instances for each group the DRG did not survive 
and it was noted that PNS did not occur in any cases where the DRG did not grow neurites 
indicating that PNS is an active process requiring interaction between the neurite 
outgrowth from the DRG and the tumour cell lines present. No significant differences in 
neurite outgrowth were observed between the DRG alone and different tumour cell line 
groups and directional outgrowth of neurites towards the cell lines did not appear to occur 
in any group. Neurite outgrowth appeared to occur in a random fashion and neurite-cell 
contact was observed to be a chance event in this model for these cell lines. Neurite-cell 
contact occurred in all instances where the DRG survived for all cell lines and once contact 
occurred all cell lines demonstrated the ability for retrograde migration along neurites 
towards the DRG of origin and PNS, showing a high propensity for PNS in the A431 cell 
line. Spread was present in 4/5 cultures with a live DRG for the parental cell line, 3/7 for 
the control cell line and 5/6 and 2/8 for the 846B and 846D knockdown lines respectively. 
A representative co-culture showing spread with the 846B knockdown cell line is shown in 
Figure 11, images taken on day 4, 7, 11 and 14 show contact between neurites and cell 
colonies at day 4 and invasion and spread over subsequent days.  
 32 
Table 3 – Mouse DRG co-culture assay with TGM3 downregulated A431 cell lines 
Co-culture	 Parental	 Control	 TGM3B	 TGM3D	
1	 Spread	 Invasion	 Nil	-	DRG	dead	 Invasion	
2	 Spread	 Nil	-	DRG	dead	 Spread	 Invasion	
3	 Nil	-	DRG	dead	 Invasion	 Nil	-	DRG	dead	 Invasion	
4	 Nil	-	DRG	dead	 Invasion	 Spread	 Spread	
5	 Spread	 Spread	 Invasion	 Invasion	
6	 Spread	 Spread	 Spread	 Spread	
7	 Nil	-	DRG	dead	 Spread	 Spread	 Invasion	
8	 Invasion	 Invasion	 Spread	 Invasion	
Nil	 3/8	(0/5)	 1/8	(0/7)	 2/8	(0/6)	 0/8	(0/8)	
Contact	 0/8	(0/5)	 0/8	(0/7)	 0/8	(0/6)	 0/8	(0/8)	
Invasion	 1/8	(1/5)	 4/8	(4/7)	 1/8	(1/6)	 6/8	(6/8)	
Spread	 4/8	(4/5)	 3/8	(3/7)	 5/8	(5/6)	 2/8	(2/8)	
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Figure 11 - Representative DRG-TGM3B co-culture demonstrating PNS in vitro 
A431-846B cell line co-cultured with mouse DRG and imaged at day 4 (upper left), day 7 (upper right), day 
11 (lower left) and day 14 (lower right). Neurite outgrowth and contact is evident at day 4 with invasion at day 
7 and spread at day 11 and day 14. 
 
An interesting observation from the co-culture assay was that once contact was 
established, migration was often seen to occur along neurites in both an anterograde and 
a retrograde direction. An example of this shown in Figure 12, in the upper panel GFP 
expressing tumour cell lines are migrating in a retrograde direction towards the DRG while 
in the lower panel migration is anterograde. 
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Figure 12 - DRG co-culture showing cell migration in both a retrograde and anterograde direction 
A431 cell line co-cultured with mouse DRG. Upper panel - Cell migration in a retrograde direction towards 
DRG (upper left) and with GFP staining transfected cells (upper right). Lower panel – A431 cell migration 
along neurites in an anterograde direction away from DRG which is not seen but positioned to the right of 
images displayed (lower left) and high power view with GFP staining transfected cells (lower right). 
 
The incidence of invasion and spread expressed as a percentage of all cultures where a 
live DRG was present is shown in Figure 13, the parental and 846B knockdown cell lines 
appeared to have a greater ability for PNS with spread occurring in 80% and 83% of 
cultures respectively compared to 43% for the control cell line and 25% for the 846D 
knockdown cell line. 
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Figure 13 – Mouse DRG co-culture assay with TGM3 downregulated A431 cell lines 
Transfected A431 cell lines co-cultured with mouse DRG. Parental = parental A431 cell line, control = 0313 
scrambled control, TGM3B = 846B knockdown, TGM3D = 846D knockdown. Data shown as incidence of 
invasion and spread displayed as a percentage of all co-cultures with a live DRG demonstrating high rates of 
PNS for the parental and TGM3B knockdown cell lines. 
 
These data demonstrate that the parental A431 cell line has a strong propensity for PNS in 
vitro, the empty vector control and two TGM3 knockdown cell lines also displayed the 
ability for migration towards and spread to the DRG in this model with spread occurring 
more frequently for the parental and 846B knockdown cell lines than the control and 846D 
knockdown lines. 
3.5.2	LOXL2	
A431 cell lines transfected to alter expression of LOXL2 were also tested using this model, 
the LOXL2 overexpression tumour cell line was compared with an empty vector control for 
their neurotrophic behaviour in vitro (Table 4). Co-cultures were assessed over a 2 week 
period and PNS was graded as nil, contact, invasion or spread as in the previous 
experiment. In cultures 1 and 2, G418 was added to the culture media to maintain 
selection pressure on transfected cell lines but DRG did not survive these conditions and 
cultures 3-8 were performed in standard culture media without inhibitors present. Again 
neurite outgrowth was seen to occur randomly with no directional outgrowth or differences 
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in neurite area between co-cultures and DRG alone cultures, no PNS was observed in any 
culture where the DRG did not survive. With the EV control group in the 6 instances where 
a live DRG was present, 2 showed spread and 4 had invasion. For the LOXL2 group there 
were 5 cultures that had a live DRG and 2 of these demonstrated spread while 1 had no 
contact, 1 had contact but no invasion and 1 had invasion but not spread. 
 
Table 4 - Mouse DRG co-culture assay with LOXL2 upregulated A431 cell lines 
Co-culture	 EV	Control	 LOXL2	
1	 Nil	-	DRG	dead	 Nil	-	DRG	dead	
2	 Nil	-	DRG	dead	 Nil	-	DRG	dead	
3	 Invasion	 Nil	-	DRG	dead	
4	 Invasion	 Nil	-	No	contact	
5	 Spread	 Invasion	
6	 Spread	 Spread	
7	 Invasion	 Contact	
8	 Invasion	 Spread	
Nil	 2/8	(0/6)	 4/8	(1/5)	
Contact	 0/8	(0/6)	 1/8	(1/5)	
Invasion	 4/8	(4/6)	 1/8	(1/5)	
Spread	 2/8	(2/6)	 2/8	(2/5)	
 
Incidence of spread and invasion expressed as a percentage of cultures that had had a 
live DRG are shown in Figure 14. These data support the view that PNS is an active 
process that requires cross talk between nerves and tumour cells, as PNS was not 
observed when a live DRG was not present. Contact appeared to be a chance event but 
once contact occurred both cell lines demonstrated that ability for invasion and spread. 
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Figure 14 – Mouse DRG co-culture assay with LOXL2 upregulated A431 cell lines 
Transfected A431 cell lines co-cultured with mouse DRG. EV control = empty vector control, LoxL2 = LoxL2 
overexpression cell line. Data shown as incidence of invasion and spread displayed as a percentage of all 
co-cultures with a live DRG demonstrating similar rates of PNS for the LOXL2 and control cell line. 
 
3.6	Optimisation	of	mouse	model	
Mouse models of PNS exist in the literature but many of the recently published models 
involve injecting tumour cells directly into the nerve and then monitoring invasion. This 
group believes that the process of tumour cells locating and gaining access to the nerve 
sheath is a crucial step in the development of PNS that is not examined by such models. 
Because of this we sought to develop a new mouse model of PNS. The aim of this model 
was to inject tumour cell lines subcutaneously into the cheek of Balb/c nude mice in the 
region of the whiskers, which is richly innervated by sensory nerve endings from the 
maxillary division of the trigeminal nerve (V2) and monitoring for perineural spread along 
this nerve. We hypothesized that if tumours could be grown subcutaneously in this location 
that it would maximize the chances of PNS becoming established due to the high density 
of nerves present and it would also be a more physiologic model of metastasis via the 
perineural route as tumour cells have to locate, invade and spread along the nerve rather 
being granted direct access to the nerve by injecting into it. This model would also 
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physiologically and anatomically reflect the human disease being studied, as the V2 nerve 
is the nerve most commonly affected by cutaneous SCC of the head and neck with PNS.  
Initially, A431 cell lines were injected subcutaneously into the cheek of ten Balb/c nude 
mice at 7.0 × 105 cells per injection to determine if tumours could be grown in this location. 
All ten mice grew subcutaneous tumours and were tolerated well by the animals, mice 
were euthanized once tumours had reached the target size and all ten mice were 
sacrificed at day 20 post injection, 2 images of a representative tumour prior to sacrifice 
are shown (Figure 15). 
 
 
Figure 15 – Balb/c nude mouse with A431 tumour right cheek 
A431 cell line inoculated into right cheek of Balb/c nude mouse at 7.0 × 105 cells per injection. Images 
displayed are 2 images of a single representative animal prior to sacrifice at day 20 post inoculation. 
 
Whole mouse heads were fixed and processed for histologic examination as described. No 
incidental PNI or PNS was observed for any of the ten mice in this experimental group but 
many nerves were observed adjacent to the margin of the tumour histologically. While no 
PNS was apparent, this initial experiment proved the utility of growing tumours 
subcutaneously in the cheek region of nude mice, showed that it was well tolerated by the 
animals and that there are many nerves present in the region to be invaded by the tumour. 
It was felt that PNS was likely to be a slow process even in an immunosuppressed animal 
model and that perhaps there had been no PNS in this initial trial due to the rapid nature of 
tumour growth causing termination of the experiment. With this in mind we wanted to 
determine the optimal cell numbers required for establishment of tumour growth. 
Subsequently a range of cell numbers from 1.0 × 105-5.0 × 105 per site were injected into 
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nude mice using A431 and Colo16 cell lines. Five animals were injected bilaterally into the 
cheek using 1.0 × 105, 2.0 × 105, 3.0 × 105, 4.0 × 105 or 5.0 × 105 cells per injection for 
each cell line. Using the A431 cell line all animals grew tumour rapidly and had to be 
euthanized on day 19, tumour volume is shown (Figure 16). 
 
 
Figure 16 - Tumour volume at day 19 A431 cell lines 100-500k 
Parental A431 cell line inoculated into 5 Balb/c nude mice bilaterally at 1.0 × 105, 2.0 × 105, 3.0 × 105, 4.0 × 
105 or 5.0 × 105 cells per injection and sacrificed at day 19 post inoculation. Tumour volume prior to sacrifice 
on day 19 is displayed for each individual tumour. 
 
Tissue was processed for histology as described and no incidental PNI or PNS was 
observed but again large numbers of nerves were visible adjacent to the tumour. As 
tumour growth was rapid even in animals inoculated with cell numbers as low as 1.0 × 105, 
the optimal cell number was estimated to be even lower and in subsequent experiments 
2.0 × 104 - 2.5 × 104 cells per site was used for the A431 cell line. Animals injected with the 
Colo16 cell line showed variable tumour growth across the range of cell numbers injected. 
At 1.0 × 105 no tumour growth was observed either macroscopically or histologically and 
the animal was sacrificed at day 60, at 2.0 × 105 one of the two injection sites grew a 
tumour and the animal was sacrificed at day 60, the animals injected with 3.0 × 105, 4.0 × 
105 and 5.0 × 105 all showed tumour growth and had to be euthanized at day 46, day 46 
and day 42 respectively, tumour volume expressed as a mean of the two sites over time is 
shown (Figure 17). 
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Figure 17 - Tumour volume for Colo16 cell lines 100-500k 
Colo16 cell line inoculated into 5 Balb/c nude mice bilaterally at 1.0 × 105, 2.0 × 105, 3.0 × 105, 4.0 × 105 or 
5.0 × 105 cells per injection and sacrificed at day 60 or once tumour volume approached 500mm3. Data is 
displayed as a mean of the two tumour sites over time. 
 
No incidental PNI or PNS was observed histologically in any of the tumours derived from 
the Colo16 cell line. The optimal cell number for subsequent experiments was determined 
to be 3.0 × 105 as this produced reliable tumour growth at the lowest cell number and 
allowed animals to be observed for the longest time period. Unfortunately as transfections 
to alter the expression of TGM3 and LOXL2 had not been successful in the Colo16 cell 
line it was not used in any subsequent experiments. 
3.7	Mouse	model	of	PNS	
3.7.1	TGM3	
Cell lines transfected to alter expression of TGM3 were tested in this new in vivo model of 
PNS. The parental A431 line along with the scrambled shRNA control line A431-0313 and 
the 2 TGM3 knockdown lines A431-846B and A431-846D were injected subcutaneously 
into the cheek of 6 week old Balb/c nude mice (Animal Resources Centre, Canning Vale, 
WA) at a concentration of 2.0 × 104 cells/injection, five animals were used for each group. 
Regular tumour measurements were collected and mice were sacrificed after 90 days or 
earlier if tumour burden was becoming large or animals appeared distressed or unhealthy. 
Due to the small cell numbers injected tumour growth was variable across the 4 groups, 2 
animals for the parental group had visible tumours, 4 from the 0313 scrambled shRNA 
control group, 4 from the 846B knockdown group and 3 from the 846D knockdown group 
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(Figure 18). Due to the small numbers involved it is difficult to draw any strong conclusions 
on any differences in tumour size across the four groups. 
 
 
Figure 18 - Tumour volume for TGM3 A431 cell lines 
Transfected A431 cell lines inoculated into Balb/c nude mice at 2.0 × 104 cells/site. Parental = parental A431 
cell line, 0313 = 0313 scrambled control, 846B = 846B TGM3 knockdown, 846D = 846D TGM3 knockdown. 
Data is displayed as tumour volume over time for each individual tumour. 
 
Whole heads from all animals were submitted for histological analysis to examine for the 
presence of incidental PNI and PNS. Transverse sections were cut at several levels 
through the tumour as well as more proximally, stained for H&E, s100 and cytokeratin 
AE1/AE3 and examined by a human pathologist. Slides were examined for the presence 
or absence of tumour and PNS which was graded as incidental if nerves within the tumour 
were involved or clinical if there was spread proximally up the V2 nerve away from the 
main tumour towards the brainstem. In the group injected with the parental A431 cell line, 
2 animals grew tumours and both demonstrated incidental PNI but there was no evidence 
of spread away from the main tumour. This result confirms what was seen with the in vitro 
DRG co-culture model that the A431 cell line has a strong propensity for PNI. Four out of 
five mice in the scrambled shRNA control group grew tumours, of these, 2 showed no 
evidence of PNI or PNS, 1 incidental PNI and 1 clinical PNI with spread up V2 towards but 
not reaching the brainstem. Of the animals injected with TGM3 downregulated cell lines, in 
the 846B group there were 4 tumours, 2 with no PNS and 2 with clinical PNI and in the 
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846D there were 3 tumours and none showed any evidence of PNS (Table 5), sections 
from a mouse head with a 846B tumour showing clinical or large nerve PNS is shown 
(Figure 19). Again with only 5 animals per group and not all animals growing tumours it is 
difficult to draw any strong conclusions on intergroup differences, it was interesting to note 
however that 50% of the animals in the 846B group that grew tumours showed large nerve 
perineural spread, the highest rate of any group. This was also consistent with the 
behaviour that this particular cell line demonstrated in the in vitro DRG assay. 
 
Table 5 - Histologic analysis of A431 TGM3 tumours 
Animal	 Parental	 Control	 TGM3B	 TGM3D	
1	 Yes	-	Incidental	 Yes	-	Clinical	 No	 No	-	Nil	Tumour	
2	 No	-	Nil	Tumour	 No	 No	-	Nil	Tumour	 No	-	Nil	Tumour	
3	 No	-	Nil	Tumour	 Yes	-	Incidental	 Yes	-	Clinical	 No	
4	 Yes	-	Incidental	 No	 Yes	-	Clinical	 No	
5	 No	-	Nil	Tumour	 No	-	Nil	Tumour	 No	 No	
Incidental	 2/5	(2/2)	 1/5	(1/4)	 0/5	(0/4)	 0/5	(0/3)	
Clinical	 0/5	(0/2)	 1/5	(1/4)	 2/5	(2/4)	 0/5	(0/3)	
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Figure 19 - Sections from mouse head with 846B tumour showing clinical PNI or PNS of right V2 
nerve (arrows) low power upper panel, high power lower panel. 
Balb/c nude mouse injected with 2.0 × 104 cells into right cheek, transverse sections taken proximal to main 
tumour. Upper panel shows whole head stained with H&E (left), cytokeratin AE1/AE3 (middle) and s100 
(right), arrows depict right V2 nerve. Lower panel shows high power view of right V2 demonstrating PNS, 
stained with H&E (left) and reciprocal staining of nerve and tumour with cytokeratin AE1/AE3 (middle) and 
s100 (right). 
3.7.2	LOXL2	
The role of LOXL2 in PNS was assessed using the in vivo model, the A431 empty vector 
control cell line and the A431 LOXL2 overexpression line were injected into the cheek of 
Balb/c nude mice (Animal Resources Centre, Canning Vale, WA). As tumour growth had 
been unpredictable with the previous group of animals a slightly increased cell number of 
2.5 × 104 cells/injection was used, 5 animals were used for each experimental group. 
Using this cell number all animals developed tumour growth and the experiment was 
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terminated at day 22 due to tumour burden and animal health, tumour volume from the 2 
groups is shown in Figure 20. While tumour volume tended to be larger for the EV control 
group this difference was not significant (p=0.28). 
 
 
Figure 20 – Tumour volume for LoxL2 A431 cell lines. 
Transfected A431 cell lines inoculated into Balb/c nude mice at 2.5 × 104 cells/site. EV control = empty 
vector control, LoxL2 = LOXL2 overexpression. Data is displayed as tumour volume over time for each 
individual tumour. 
 
Mouse heads from all ten animals were submitted for histological examination as in the 
TGM3 experiments. No tumours from either group showed histologic evidence of PNS 
while 4/5 animals from the empty vector control group had incidental PNI and 2/5 from the 
LOXL2 group had incidental PNI which was graded as extensive in these tumours (Table 
6). 
 
Table 6 – Histologic analysis of A431 LOXL2 tumours 
Animal	 EV	Control	 LOXL2	
1	 No	 Yes	–	Incidental	(Extensive)	
2	 Yes	–	Incidental	 No	
3	 Yes	–	Incidental	 No	
4	 Yes	–	Incidental	 Yes	–	Incidental	(Extensive)	
5	 Yes	–	Incidental	 No	
Incidental	 4/5	(4/5)	 2/5	(2/5)	
Clinical	 0/5	(0/5)	 0/5	(0/5)	
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While lower rates of PNS was not the expected result for the LOXL2 group, in the tumours 
that did show PNI it was found to be more extensive than in the control group therefore not 
ruling out a role for LOXL2 in metastasis via the perineural route. 
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Chapter	4	-	Discussion	
4.1	Transfection	of	cell	lines	
The cell lines Colo16 and A431 were selected for use in this study due to their close 
resemblance to human epithelial SCC the disease process being studied, their availability 
in the laboratory and laboratory experience with cell line behaviour in tissue culture. This 
group also had previous experience in modifying expression of genes in these cell lines 
and establishing tumours derived from Colo16 cell lines in nude mice, making these cell 
lines the ideal choice for this work. 
Transfection of the A431 cell line produced stable knockdown of TGM3 by two of the 
shRNA constructs (846B and 846D), these two knockdown lines were selected for use in 
ongoing experiments and compared against the parental A431 cell line and the A431 cells 
transfected with the scrambled shRNA control (0313). Two knockdown lines produced 
using different shRNA constructs were used to minimise the chances of off-target effects 
causing modulation of unintended genes and erroneous results. It is not understood why 
transfection of the Colo16 cell line was not successful in producing any stable knockdown 
of TGM3 by any of the four shRNA constructs. The transfection process was successful as 
confirmed by the presence of antibiotic resistance and expression of GFP by the 
transfected cells but no change in TGM3 expression was detected by western blot. 
However, similar results have been observed for other genes, where shRNA targeting has 
been unsuccessful in Colo16 potentially implicating a deficiency in the cell line (Boyle, 
personal communication). 
Western blot analysis of the LOXL2 cell lines confirmed overexpression of LOXL2 in the 
A431 cell line but again no altered expression was observed in the Colo16 line. The A431 
LOXL2 overexpression line was used in subsequent experimental assays paired with its 
empty vector control line (EV control). 
The cell lines available provided a useful resource for studying the role of TGM3 and 
LOXL2 in PNS in vitro and in vivo using the models employed in this research. 
4.2	Proliferation	assay	
SRB assays to assess in vitro proliferation ability of transfected A431 cell lines were 
performed to assess malignant potential of these cell lines. Results consistently 
demonstrated a reduced proliferation ability of the TGM3 downregulated cell line (A431-
846B). It is interesting to note that the other TGM3 knockdown cell line (A431-846D) 
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performed inconsistently in this assay, on one occasion showing reduced proliferative 
capacity similar to that for the A431-846B line while on another occasion performing 
equally to the parental and control cell lines. While performance in a proliferation assay in 
vitro is considered to be a predictor of malignant potential in vivo there is no data 
confirming this is the case for PNS, therefore reduced proliferation for the TGM3 
knockdowns did not necessarily predict a reduced ability for PNS in subsequent assays. 
4.3	Colony	forming	assay	
The transfected A431 cell lines were run in a standard colony forming assay and the 
results showed that the transfected cell lines including the scrambled shRNA control A431-
0313 and the two TGM3 knockdown lines A431-846B and A431-846D showed reduced 
colony forming ability compared with the parental A431 cell line. This implies that the 
transfection process itself had a negative effect on the clonogenicity of these cell lines as 
evidenced by the difference between the parental and control lines. Also the two TGM3 
knockdown lines showed an additional significant reduction in colony forming ability 
compared to the empty vector control line suggesting that knocking down TGM3 also 
negatively effected clonogenicity. Again while increased colony forming capacity in vitro is 
considered a predictor of malignant potential and the TGM3 downregulated cell lines 
showed reduced capacity for clonogenicity in vitro this does not necessarily correlate with 
a predilection for PNS. Therefore despite an apparent reduced colony forming and 
proliferation capacity of TGM3 downregulated cell lines in vitro we proceeded to assess 
these cell lines for neurotrophic behaviour using in vitro and in vivo assays. 
4.4	Optimisation	of	DRG	co-culture	assay	
A DRG tumour cell co-culture assay was developed as a tool to study PNS in prostate 
cancer as this is a common route of metastatic spread in this disease (12). This model has 
since been adopted by others to study PNS in pancreatic cancer (67) and SCC of the head 
and neck (64). In this study we wanted to assess the neurotrophic potential of our cell lines 
with altered expression of TGM3 and LOXL2 in vitro using this model. As discussed in the 
results section, initial trials using this model and the parental Colo16 cell line were 
unsuccessful due to difficulties controlling the relative positions of the DRG and cell lines in 
the fluid Matrigel. We attempted to overcome these problems by first plating the cell lines 
into Ibidi cell culture inserts and allowing them to become adherent before removing the 
insert and plating the DRG adjacent to the cell lines and covering both with a drop of 
Matrigel. This method was used to examine the parental Colo16 cell line and the TGM3 
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downregulated A431 cell lines and results are shown Figure 9 and Figure 10. It was 
observed that the modifications to the method with tumour cell lines adherent to the culture 
vessel and covered with Matrigel made the cells unable to migrate and even affected their 
ability to proliferate and survive. The published data on this method reports increased 
neurite outgrowth in the presence of prostate cancer cells and directional outgrowth of 
neurites towards the tumour cells followed by contact, retrograde migration and invasion 
(12), the authors suggest that this supports the hypothesis that PNS is an active and 
reciprocal interaction with tumour cells providing signals to nerves to stimulate and direct 
neurite outgrowth. Changes in neurite outgrowth were not observed in the presence of 
tumour cells in our modified model. Neurite outgrowth was seen to be equal between DRG 
cultured alone and DRG co-cultured with the various cell lines and no directional outgrowth 
of neurites towards the cell lines was observed, contact was observed but there was no 
invasion or spread. These results suggest either that the cell lines tested are not capable 
of interacting with and invading the DRG or that the changes to the model have affected its 
functionality. Due to concerns with the latter the modifications to the co-culture model were 
abandoned and it was run using the published model for all the subsequent experiments. 
4.5	DRG	co-culture	assay	
4.5.1	TGM3	
Cell lines with altered expression of TGM3 showed a high propensity for PNS in the in vitro 
DRG co-culture model. The original authors describe PNS in this model as an active 
process that requires crosstalk between tumour cells and the DRG for PNS to occur. The 
data shown here support this in the sense that PNS did not occur if the DRG did not 
survive in culture but certain specific phenomena were not observed. The authors describe 
increased neurite outgrowth in the presence of tumour cells, directional neurite outgrowth 
towards tumour cells and migration of tumour cells towards neurites. In this study however 
no changes in neurite outgrowth were seen in the presence of tumour cells and tumour cell 
migration appeared to be random until contact between cells and neurites occurred. Only 
once contact was established did we observe specific migration of cells along the neurites 
towards the DRG of origin. In some instances tumour cells were noted to migrate along 
neurites in an anterograde direction away from the DRG further suggesting that while 
migration appeared to be an active process it was not occurring under the guidance of a 
secreted mediator for these cell lines in this model. PNI and PNS were seen in all 
instances where a live DRG was present, the highest rates of PNS were observed for the 
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parental A431 cell line and the A431-846B knockdown line. Lower rates of PNS were seen 
for the scrambled shRNA control and the A431-846D knockdown line and these results are 
difficult to explain. 
4.5.2	LOXL2	
When this in vitro assay was used to assess the LOXL2 overexpression line similar results 
were seen. The cell lines showed neurotrophic behaviour that was again dependent on a 
live DRG being present but no specific interaction was seen until after contact occurred. 
Similar rates of PNS were observed for the EV control and LOXL2 overexpression lines 
while the overexpression lines showed a reduced incidence of PNI compared to the EV 
control. These results supported this in vitro DRG co-culture model as a valuable tool for 
studying PNS, due to the high levels of neurotrophic behaviour that were seen in the un-
modified A431 cell line it would have been difficult to observe in increase in neurotrophism 
in any of the modified lines. It is also possible that the reduced proliferation and colony 
forming ability of the transfected cell lines affected the performance of these cell lines in 
this assay. 
4.6	Optimisation	of	mouse	model	
Currently available mouse models establish PNS by injecting directly into the nerve and 
allowing PNS to progress. We feel that this bypasses certain critical steps in the process of 
PNS namely migration towards and invasion of the nerve and we wanted to develop a 
more physiologic model to study this entire process. The tumour cell lines A431 and 
Colo16 were injected into the cheek of Balb/c nude mice adjacent to sensory nerve 
endings of the V2 nerve to determine if tumours could be established, what was the ideal 
cell concentration required to establish tumour growth and if any PNS could be 
demonstrated using the parental cell lines. It was assumed that it would take time for PNS 
to become established and the aim was to determine a cell line and inoculation dose that 
would result in reliable formation of tumour and a slow rate of tumour progression allowing 
time for PNS to occur. Results showed that tumours could be grown reliably in this location 
using both the A431 and the Colo16 cell line. One limitation of locating the tumour on the 
face was that as tumour burden increased it reached a size that affected animal welfare 
relatively quickly, it was observed that once tumour volume reached 500 mm3 animals 
began to loose weight due to malocclusion and associated reduced oral intake and 
subsequent experiments had to be terminated prior to tumour burden reaching this point. It 
wasn’t clear initially whether there would be time for PNS to occur before tumours reached 
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this maximal size and this is one potential advantage of locating the tumour adjacent to a 
more peripheral nerve such as the sciatic as utilised by other groups. The A431 cell line 
was clearly more aggressive in vivo showing rapid tumour growth at the lowest 
concentration used of 1.0 × 105 cells per injection, as no PNS was observed the optimal 
cell number was estimated to be even lower and in subsequent experiments 2.0 × 104 - 2.5 
× 104 cells per site was used for this cell line.  The ideal inoculation dose for the Colo16 
cell line was demonstrated to be 3.0 × 105 cells as this was the lowest dose that allowed 
reliable tumour growth and a long duration of animal survival post injection. A total of 
twenty-seven tumours from these trial experiments were submitted for histology and 
examined for PNS (A431 n = 20 and Colo16 n = 7). While no microscopic PNI or PNS was 
observed in any of these tumours it was encouraging to find that large numbers of nerves 
were visible around the margin of the tumour. This observation confirmed the hypothesis 
that the cheek of the mouse contained a very high density of sensory nerves for tumour 
cells to invade and that this model closely mimicked the disease process being examined. 
4.7	Mouse	model	of	PNS	
4.7.1	TGM3	
The described in vivo model was used to assess the neurotrophic behaviour of cell lines 
with altered expression of TGM3. The two control cell lines and two TGM3 knockdown 
lines were injected at 2.0 × 104 per site as determined by the optimisation experiments. At 
this concentration tumour growth was variable and not all animals showed tumour growth. 
Variable tumour growth made it difficult to draw strong comparisons between groups but 
tumour burden appeared to be equal across the four groups of animals. As previously 
stated our experience is that aggressive tumour growth does not always correlate with 
increased ability for PNS so we did not necessarily expect TGM3 knockdown lines to 
display altered tumour growth in vivo. When tumours from these animals were examined 
for PNS histologically interesting results were obtained despite the small numbers of 
tumours grown. The parental A431 cell line displayed the highest rate of incidental PNI 
(2/2) but no clinical PNI or PNS while the A431-846B cell line displayed the highest rate of 
clinical PNI or PNS (2/4). These data suggest that knockdown of TGM3 resulted in a 
change of phenotype from favouring incidental PNI towards large nerve PNS. It also 
proves the utility of this new model for studying PNS, demonstrating that tumours 
implanted subcutaneously in the cheek could gain access to the V2 nerve and spread 
proximately towards the brain stem. It would have been interesting to see if tumours would 
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have reached the brainstem if the experiment had continued longer but the size of the 
primary lesion did not allow for this to occur. In the human disease the cutaneous primary 
lesion has usually been excised some time before PNS is detected and it is possible in 
future studies using this model that the primary could be excised or debulked to allow for 
further spread along the nerve to the CNS. We also noted that when PNS was present in 
this model that spread was contiguous without the presence of skip lesions and that once 
in the nerve the tumour respected the perinerium and spread progressively along rather 
than destroy and break out of the nerve exactly mimicking the human condition. Results 
here show this new model to be a valuable tool in the study of PNS and support the 
hypothesis that downregulation of TGM3 results in a switch in phenotype to one favouring 
PNS. 
4.7.2	LOXL2	
The LOXL2 overexpression cell line was tested in the same in vivo model, due to variable 
tumour growth in the TGM3 group a slightly increased inoculation number of 2.5 × 104 per 
site was used. The result was more predictable establishment of tumour but more 
aggressive tumour growth and all animals had to be euthanized on day 22. Tumour growth 
tended to be slower in the group over expressing LOXL2 and again this is in line with what 
is seen clinically but this difference was not significant. The control group again displayed 
high levels of incidental PNI (4/5) but no clinical PNI or PNS while the LOXL2 
overexpression group showed a lower incidence of incidental PNI (2/5). No PNS was 
observed for either group but this may have been due to the short duration of the 
experiment. In the previous experiment using the TGM3 cell line the tumours that 
demonstrated PNS were culled on day 25, 42 and 45 so it is likely that there was 
inadequate time for PNS to become established in this trial. Unfortunately this meant that 
no difference in the rate of PNS was seen between the two groups and tells us that while 
2.0 × 104 cells per injection results in variable tumour growth it is the ideal cell number for 
the A431 cell line in this model as it produces less aggressive tumour growth and allows 
time for PNS. 
4.8	Final	discussion	
Here we describe a new in vivo model of PNS that fully examines the process of PNS 
where tumour cells locate, infiltrate and spread along nerves away from the primary lesion. 
Using this model we demonstrate that cell lines with reduced expression of TGM3 had a 
greater propensity for PNS compared to control cell lines. This information could be used 
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as a prognostic indicator for patients with PNI and aid in deciding which patients may 
benefit from more aggressive treatment of the primary lesion in the form of more 
aggressive surgery or adjuvant radiotherapy. 
We were unable to confirm a role for overexpression of LOXL2 however this may have 
been due to aggressive tumour growth leading to early termination of this experiment. The 
main limitation of this new model is that locating the tumour on the face limits the size of 
the primary tumour that can be tolerated by the animal. This limits the duration of the 
experiment, as animals have to be sacrificed once the tumour reaches a size that affects 
animal welfare. We attempted to overcome this problem by inoculating with very small cell 
numbers but this tended to result in variable tumour growth. This could be overcome in 
future experiments by using a lentiviral delivery system where cells could be induced to 
express a shRNA or over-express the protein of interest using uninduced cells as a 
control. An antibody targeting LOXL2 has been developed and tested for preventing 
metastases in other human cancers and could be useful in the treatment of PNS if it could 
be proven to be mechanistically involved. 
Gaining a better understanding of the molecular pathways that drive this neurotrophic 
behaviour will allow for improved treatment strategies for patients suffering from this 
important form of tumour metastasis. 
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